Loading...
Mechanisms of Nuclear Export in Cancer and Resistance to Chemotherapy
El-Tanani, Mohamed Dakir, El-Habib Raynor, Bethany Morgan, Richard
El-Tanani, Mohamed
Dakir, El-Habib
Raynor, Bethany
Morgan, Richard
Publication Date
2016-03-14
End of Embargo
Supervisor
Rights
© 2016 The Authors. This is an Open Access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/)
Peer-Reviewed
Yes
Open Access status
openAccess
Accepted for publication
2016-03-08
Institution
Department
Awarded
Embargo end date
Collections
Additional title
Abstract
Tumour suppressor proteins, such as p53, BRCA1, and ABC, play key roles in preventing the development of a malignant phenotype, but those that function as transcriptional regulators need to enter the nucleus in order to function. The export of proteins between the nucleus and cytoplasm is complex. It occurs through nuclear pores and exported proteins need a nuclear export signal (NES) to bind to nuclear exportin proteins, including CRM1 (Chromosomal Region Maintenance protein 1), and the energy for this process is provided by the RanGTP/RanGDP gradient. Due to the loss of DNA repair and cell cycle checkpoints, drug resistance is a major problem in cancer treatment, and often an initially successful treatment will fail due to the development of resistance. An important mechanism underlying resistance is nuclear export, and a number of strategies that can prevent nuclear export may reverse resistance. Examples include inhibitors of CRM1, antibodies to the nuclear export signal, and alteration of nuclear pore structure. Each of these are considered in this review.
Version
Published version
Citation
El-Tanani M, Dakir E, Raynor B et al (2016) Mechanisms of Nuclear Export in Cancer and Resistance to Chemotherapy. Cancers. 8(3): 35
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article